# Gilteritinib-Fumarate-Market-Report
Gilteritinib Fumarate is estimated to rise to $3091.5 million by 2035 from $587.2 million of 2024. The revenue growth of market players is expected to average at 16.3% annually for the period 2024 to 2035.
